NCT03811574 - STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity | Biotech Hunter

Enrollment

401

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions

OverweightObesity

Interventions

DRUG

Semaglutide

Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.

DRUG

Placebo (semaglutide)

Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.

Trial Locations (28)

13620

Novo Nordisk Investigational Site, Gyeonggi-do

123-0845

Novo Nordisk Investigational Site, Adachi-ku, Tokyo

113-8655

Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo

066-0032

Novo Nordisk Investigational Site, Chitose, Hokkaido

103-0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

103-0025

Novo Nordisk Investigational Site, Chuo-ku,Tokyo

373-0036

Novo Nordisk Investigational Site, Gunma

311-0113

Novo Nordisk Investigational Site, Ibaraki

232-0064

Novo Nordisk Investigational Site, Kanagawa

582-0005

Novo Nordisk Investigational Site, Kashiwara-shi, Osaka

650-0017

Novo Nordisk Investigational Site, Kobe, Hyogo

862-0976

Novo Nordisk Investigational Site, Kumamoto

880-0034

Novo Nordisk Investigational Site, Miyazaki

004-0004

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

329-0433

Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi